Vir Biotechnology Inc has a consensus price target of $32.42, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., JP Morgan, and HC Wainwright & Co. on March 15, 2024, February 23, 2024, and February 14, 2024. With an average price target of $76.67 between HC Wainwright & Co., JP Morgan, and HC Wainwright & Co., there's an implied 904.81% upside for Vir Biotechnology Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/15/2024 | VIR | Buy Now | Vir Biotechnology | $7.63 | 1341.68% | HC Wainwright & Co. | Patrick Trucchio | → $110 | Reiterates | Buy → Buy | Get Alert |
02/23/2024 | VIR | Buy Now | Vir Biotechnology | $7.63 | 31.06% | JP Morgan | Eric Joseph | $9 → $10 | Maintains | Neutral | Get Alert |
02/14/2024 | VIR | Buy Now | Vir Biotechnology | $7.63 | 1341.68% | HC Wainwright & Co. | Patrick Trucchio | $85 → $110 | Maintains | Buy | Get Alert |
01/29/2024 | VIR | Buy Now | Vir Biotechnology | $7.63 | 17.96% | JP Morgan | Eric Joseph | $23 → $9 | Downgrade | Overweight → Neutral | Get Alert |
01/23/2024 | VIR | Buy Now | Vir Biotechnology | $7.63 | 1014.02% | HC Wainwright & Co. | Patrick Trucchio | $95 → $85 | Maintains | Buy | Get Alert |
11/03/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 96.59% | Needham | Joseph Stringer | $22 → $15 | Maintains | Buy | Get Alert |
09/08/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 83.49% | B of A Securities | Geoff Meacham | $23 → $14 | Downgrade | Buy → Neutral | Get Alert |
08/07/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 1145.09% | HC Wainwright & Co. | Patrick Trucchio | $100 → $95 | Maintains | Buy | Get Alert |
08/04/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 188.34% | Needham | Joseph Stringer | → $22 | Reiterates | Buy → Buy | Get Alert |
07/21/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 96.59% | Morgan Stanley | Michelle Gilson | $27 → $15 | Maintains | Equal-Weight | Get Alert |
07/21/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 266.97% | Goldman Sachs | Paul Choi | $51 → $28 | Maintains | Buy | Get Alert |
07/21/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 437.35% | Barclays | Gena Wang | $59 → $41 | Maintains | Overweight | Get Alert |
07/20/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 188.34% | Needham | Joseph Stringer | $32 → $22 | Maintains | Buy | Get Alert |
07/20/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 1210.62% | HC Wainwright & Co. | Patrick Trucchio | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
05/05/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 319.4% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
04/19/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 319.4% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
04/04/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 253.87% | Morgan Stanley | Michelle Gilson | $25 → $27 | Maintains | Equal-Weight | Get Alert |
03/06/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 1210.62% | HC Wainwright & Co. | Patrick Trucchio | $125 → $100 | Maintains | Buy | Get Alert |
03/06/2023 | VIR | Buy Now | Vir Biotechnology | $7.63 | 345.61% | JP Morgan | Eric Joseph | $35 → $34 | Upgrade | Neutral → Overweight | Get Alert |
The latest price target for Vir Biotechnology (NASDAQ: VIR) was reported by HC Wainwright & Co. on March 15, 2024. The analyst firm set a price target for $110.00 expecting VIR to rise to within 12 months (a possible 1341.68% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for Vir Biotechnology (NASDAQ: VIR) was provided by HC Wainwright & Co., and Vir Biotechnology reiterated their buy rating.
The last upgrade for Vir Biotechnology Inc happened on March 6, 2023 when JP Morgan raised their price target to $34. JP Morgan previously had a neutral for Vir Biotechnology Inc.
The last downgrade for Vir Biotechnology Inc happened on January 29, 2024 when JP Morgan changed their price target from $23 to $9 for Vir Biotechnology Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vir Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vir Biotechnology was filed on March 15, 2024 so you should expect the next rating to be made available sometime around March 15, 2025.
While ratings are subjective and will change, the latest Vir Biotechnology (VIR) rating was a reiterated with a price target of $0.00 to $110.00. The current price Vir Biotechnology (VIR) is trading at is $7.63, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.